William Edward Boden, MD

Professor, Medicine

William Boden
150 South Huntington Avenue


I am ABIM board-certified in both Internal Medicine and the subspecialty of Cardiovascular Disease. Since 1979, I have held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, State University of New York in Buffalo, and Albany Medical College. For the past 27 consecutive years, I have held leadership roles as either a Chief of cardiology or Chief of Medicine at both federal VA facilities and in the academic private sector, all of which have had strong affiliations with their respective academic health centers. In 2016, I re-joined the VA Boston MAVERIC Center as the Scientific Director, Clinical Trials Network, for the VA New England Healthcare System, and as the Research Lead Physician, for VISN 1.

I have extensive prior experience in clinical trials and comparative effectiveness research, and have served in a leadership capacity in several important national and international clinical trials, including as Study Chair for VA CSP-funded VANQWISH and COURAGE Trials, as Study Co-Chair of the NIH-funded AIM-HIGH Trial, and as a national co-PI for the NIH-funded ISCHEMIA Trial. My principal research interests include studies in stable ischemic heart disease, post-MI secondary prevention, acute coronary syndromes, and preventive cardiology.

Other Positions

  • Lecturer in Medicine, Harvard Medical School
  • Physician Research Lead & Scientific Director, Clinical Trials Network, MAVERIC Center, VA Boston Healthcare System


  • State University of New York at Brockport, MD
  • Le Moyne College, BS


  • Published on 4/7/2024

    Kaski JC, Al-Lamee R, Boden WE. The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease. Eur Heart J. 2024 Apr 07; 45(14):1201-1204. PMID: 38442290.

    Read at: PubMed
  • Published on 2/27/2024

    Reynolds HR, Cyr DD, Merz CNB, Shaw LJ, Chaitman BR, Boden WE, Alexander KP, Rosenberg YD, Bangalore S, Stone GW, Held C, Spertus J, Goetschalckx K, Bockeria O, Newman JD, Berger JS, Elghamaz A, Lopes RD, Min JK, Berman DS, Picard MH, Kwong RY, Harrington RA, Thomas B, O'Brien SM, Maron DJ, Hochman JS. Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial. J Am Heart Assoc. 2024 Mar 05; 13(5):e029850. PMID: 38410945.

    Read at: PubMed
  • Published on 2/7/2024

    Gaba P, Bhatt DL, Boden WE. Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use. Eur Heart J. 2024 Feb 07; 45(6):439-442. PMID: 37889071.

    Read at: PubMed
  • Published on 2/1/2024

    Gaudino M, Flather M, Capodanno D, Milojevic M, Bhatt DL, Biondi Zoccai G, Boden WE, Devereaux PJ, Doenst T, Farkouh M, Freemantle N, Fremes S, Puskas J, Landoni G, Lawton J, Myers PO, Redfors B, Sandner S. European Association of Cardio-Thoracic Surgery (EACTS) expert consensus statement on perioperative myocardial infarction after cardiac surgery. Eur J Cardiothorac Surg. 2024 Feb 01; 65(2). PMID: 38420786.

    Read at: PubMed
  • Published on 12/29/2023

    Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P. Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc. 2024 Jan 02; 13(1):e032413. PMID: 38156550.

    Read at: PubMed
  • Published on 12/15/2023

    Gulati M, Michos ED, Boden WE, Guyton JR. JCL roundtable: Evolution of preventive cardiology and clinical lipidology. J Clin Lipidol. 2024; 18(1):e10-e20. PMID: 38245457.

    Read at: PubMed
  • Published on 12/8/2023

    Boden WE. Optimal medical therapy vs revascularization in chronic coronary syndromes: Does ISCHEMIA move the needle toward or away from revascularization?? Vascul Pharmacol. 2024 Mar; 154:107253. PMID: 38070758.

    Read at: PubMed
  • Published on 10/19/2023

    Yuyun MF, Joseph J, Erqou SA, Kinlay S, Echouffo-Tcheugui JB, Peralta AO, Hoffmeister PS, Boden WE, Yarmohammadi H, Martin DT, Singh JP. Persistence of significant secondary mitral regurgitation post-cardiac resynchronization therapy and survival: a systematic review and meta-analysis : Mitral regurgitation and mortality post-CRT. Heart Fail Rev. 2024 Jan; 29(1):165-178. PMID: 37855988.

    Read at: PubMed
  • Published on 9/21/2023

    Weintraub WS, Boden WE. Can we measurably improve the prediction of recurrent coronary artery disease events? Eur Heart J. 2023 Sep 21; 44(36):3466-3468. PMID: 37738645.

    Read at: PubMed
  • Published on 9/19/2023

    Barili F, Anselmi A, Boden WE, Sousa Uva M, Parolari A. Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial. J Am Coll Cardiol. 2023 Sep 19; 82(12):e101. PMID: 37704317.

    Read at: PubMed

View 385 more publications: View full profile at BUMC

View all profiles